Aurion Biotech has pushed out its CEO. Swiss healthcare company Alcon last week acquired a majority interest in Aurion, a clinical-stage startup in Seattle that is developing advanced cell ...

Please provide your email address to receive an email when new articles are posted on . Aurion will operate as a separate company. The Aurion board appointed Arnaud Lacoste, PhD, as CEO.

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

(RTTNews) - Aurion Resources Ltd. (AU.V) Wednesday has finalized an agreement with KoBold Exploration Finland Oy, a subsidiary of KoBold Metals Company, granting KoBold a 75% interest in a 35 km² ...

Aurion Resources (TSXV: AU) is teaming up with KoBold Metals, the mineral exploration company backed by Jeff Bezos and Bill Gates, to unlock the critical minerals potential of its Risti project in ...

Joint venture: Following satisfaction by KoBold of the earn-in requirements, a joint venture will be established with KoBold owning 75% and Aurion 25%. Net smelter returns royalty: In case an ...

Age of Mythology: Retold, from that legendary publisher of video games, Xbox Games Studios, is coming to PS5 on 4th March. The seminal strategy game was initially developed by Ensemble Studios ...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies ...

“We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion’s CEO. “Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the public market, a decision Alcon says it will move to appeal. Cell therapy ...

Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors. The eye-disease-focused company plans to list on the New York ...